![Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension](https://www.ahajournals.org/cms/asset/e30b1ac4-076a-4352-85fa-00d2d9d3d914/hy10t0033002.jpg)
Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension
![Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling](https://www.science.org/cms/asset/251b44a4-d8ca-4efd-8338-c056b1bcb704/signaling.2015.8.issue-406.largecover.jpg)
Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling
![Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling](https://www.science.org/cms/asset/dd3c22d5-170b-46dc-8493-7c848f999705/8_ra125_f1.gif)
Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas | Science Signaling
![Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension](https://www.ahajournals.org/cms/asset/25da5f96-fd4a-476b-bce2-107baf0db96f/hy10t0033003.jpeg)
Gender Differences in Ca2+ Entry Mechanisms of Vasoconstriction in Wistar-Kyoto and Spontaneously Hypertensive Rats | Hypertension
![PDF) Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? PDF) Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?](https://i1.rgstatic.net/publication/358162088_Validating_Cell_Surface_Proteases_as_Drug_Targets_for_Cancer_Therapy_What_Do_We_Know_and_Where_Do_We_Go/links/61fd39701abad353168a1a9c/largepreview.png)